Dr Daniel Ang Jia Ming

Dr. Daniel Ang is an Associate Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore. He has a strong interest in translational and clinical research in genitourinary and thoracic oncology, particularly in experimental therapeutics and bio-marker discovery.

He obtained his medical degree from Imperial College London with distinction in Medical Sciences, Clinical Science and Clinical Practice. He completed his specialist training in Medical Oncology in Singhealth Hospitals. Dr. Ang’s research has been presented at international conferences, including the European Society of Medical Oncology (ESMO) Asia and the Japan So-ciety of Medical Oncology (JSMO) Congresses, and published in peer-reviewed journals such as JCO Precision Oncology and the Journal of Gynecologic Oncology.

A recipient of multiple academic and profession awards, Dr. Ang is also dedicated to medical education and quality improvement. His clinical and research work aims to improve patient outcomes through scientific innovation and improving drug access.

• MMed (Internal Med.), National University Singapore, 2021 
• MRCP (UK), Royal College of Physicians, 2021 
• MBBS (Hons), Imperial College London, 2018 
• BSc (Hons), Imperial College London, 2016

• European Society of Medical Oncology, Member (2024 – current)
• American Society of Clinical Oncology, Member (2023 – current) 
• Royal College of Physicians (United Kingdom), Member (2021 – current)

• 2025 Singhealth RiSE Outstanding Resident Award 
• 2025 Japan Society of Medical Oncology Travel Award 
• 2025 Japan Society of Medical Oncology – Rising Stars in Asia Workshop Award 
• 2024 Singhealth RiSE Inspiring Resident Educator Award 
• 2023 National Cancer Centre Singapore Quality Improvement Project Winner 
• 2018 Faculty of Medicine Best Overall Performance Prize, Imperial College School of Medicine 
• 2018 Gordon M Holmes Prize, Imperial College School of Medicine 
• 2017 HWC Vines Prize (proxime accessit), Imperial College School of Medicine 
• 2017 Richard Hebb Prize, Imperial College School of Medicine
• 2016 Charles Power Prize, Imperial College School of Medicine 
• 2016 Hepburn Memorial Prize, Imperial College School of Medicine 
• 2016 Thomas Skurry Prize, Imperial College School of Medicine 
• 2015 Chadwick Prize, Imperial College School of Medicine 
• 2015 Swinford Evans Gold Prize, Imperial College School of Medicine 
• 2015 Rudolph Konstamm Silver Prize, Imperial College School of Medicine 
• 2013 Martin J Turner Scholarship Prize, Imperial College School of Medicine

• Ang DJM, Farid M. Re-evaluating adjuvant systemic therapy in cancer treatment: Scientific rigour to guide policy and practice, Annals Academy of Medicine Singapore, 2025; 54(4):247-251. 
• Ang DJM, Bok KX, Wong SL, Li Y, Wong A, Bok KX, Wong SL, Li Y, Wong A, Yeo YC, Wang J, Aggarwal IM, Chan JJ. Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience, Gynecologic Oncology Reports, 2025; 58. 
• Ang DJM, Chan J, Ong WS, Tan HS, Ng QS, Yuen J, Chen K, Tay KJ, Wong SW, Saad M, Nagata M, Horie S, Chansriwong P, Ng CF, Wong A, Chua MLK, Toh CK, Tan MH, Lim T, Bhagat A, Kanesvaran R. Androgen receptor splice variant 7 in Asian patients with metastatic castration-resistant prostate cancer, JCO Precision Oncology, 2024 Jun:8:e2300694 
• Ang DJM, Chan JJ. Evolving standards and future directions for systemic therapies in cervical cancer, Journal of Gynecologic Oncology, 35;2024 
• Loh CH, Koh PW, Ang DJM, Lee WC, Chew WM, Koh JMK. Characteristics of Singapore lung cancer patients who miss out on lung cancer screening recommendations, Singapore Med J, 2022:1-22